We have received your feedback.Thank you for taking your time in view of your busy schedule.
| Weekly News | Amount |
|---|---|
|
Total
|
${lastRankDetail.pages.length} |
| Financing | ${lastRankDetail.financing_pages.length} |
| Product | ${lastRankDetail.product_pages.length} |
| Negative | ${lastRankDetail.sentiment_pages.length} |
Sciwind Biosciences is a drug developer for metabolic diseases. The company is mainly engaged in the research of drugs for fatty hepatitis, liver fibrosis, liver cirrhosis and other related metabolic diseases, and involves the research and development of new biological drugs with independent intellectual property rights
Transactions
Research
Competition
Transactions
Funding
2 Fundings
| Date | Amount | Round | Relative News |
|---|---|---|---|
| Feb 2019 | 200 million CNY | Series A | Sciwind Biosciences received nearly 200 million yuan in Series A financing, and laid out NASH new drugs |
| Feb 2021 | 250 million CNY | Series B | Sciwind Biosciences completed the B round of financing of RMB 250 million |
Signals
Events
${currentEventsPage.count} Events
| Events (${currentEventsPage.count}) | Date |
|---|---|
| Nothing Happens :-( | |
| ${e.desp} | ${e.date} |
News
${ rankDetail.pages.length } News Articles
${currentTimeRange.start} ~ ${currentTimeRange.end}
| Article (${rankDetail.pages.length}) | Tag |
|---|---|
| ${article.en_title} | ${article.tag} |
Industry Financing Info
Research
Intelligence
0 Research Briefs
Competition
Competitors
5 Competitors
